嵌合抗原受体t细胞治疗滤泡性淋巴瘤的研究进展

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-10-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.10.018

Hailing Ning

{"title":"嵌合抗原受体t细胞治疗滤泡性淋巴瘤的研究进展","authors":"Hailing Ning","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.018","DOIUrl":null,"url":null,"abstract":"Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL. \n \n \nKey words: \nLymphoma, follicular; Chimeric antigen receptor T-cell; CD19; Anti-CD20 monoclonal antibody","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"717-720"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress of chimeric antigen receptor T-cell for treatment of follicular lymphoma\",\"authors\":\"Hailing Ning\",\"doi\":\"10.3760/CMA.J.ISSN.1006-9801.2019.10.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL. \\n \\n \\nKey words: \\nLymphoma, follicular; Chimeric antigen receptor T-cell; CD19; Anti-CD20 monoclonal antibody\",\"PeriodicalId\":9505,\"journal\":{\"name\":\"肿瘤研究与临床\",\"volume\":\"31 1\",\"pages\":\"717-720\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"肿瘤研究与临床\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

滤泡性淋巴瘤（FL）通常是隐匿性的，有广泛的疾病表现和预后。近年来，随着抗CD20单克隆抗体和标准化疗方法的结合，以及免疫调节剂和造血干细胞移植的使用，FL患者的生存率大大提高，但它仍然被认为是一种不治之症。最近的研究表明，嵌合抗原受体T细胞（CAR-T）治疗可以提高FL患者的生存率和预后。本文将详细阐述CAR-T治疗FL的机制、临床研究进展、不良反应及局限性；嵌合抗原受体T细胞；CD19；抗CD20单克隆抗体

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Progress of chimeric antigen receptor T-cell for treatment of follicular lymphoma

Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL. Key words: Lymphoma, follicular; Chimeric antigen receptor T-cell; CD19; Anti-CD20 monoclonal antibody

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.